Key Takeaways TEM gained 34.5% in Q2, outperforming the sector and peers like TXG and SOPH.A $200M AI partnership with AstraZeneca and Pathos is set to drive long-term data monetization for TEM.Despite top-line strength, TEM's valuation premium and lack of profitability may weigh on near-term upside.Tempus AI, Inc. (TEM) is scheduled to report second-quarter 2025 results on Aug. 8.In the last reported quarter, the company’s adjusted loss of 24 cents was narrower than the Zacks Consensus Estimate of a loss o ...